Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. 2009

Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
Département de Microbiologie et Infectiologie, Hôpital Notre-Dame du Centre Hospitalier de l'Université de Montréal, Département de Médecine Familiale, Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada.

BACKGROUND Human immunodeficiency virus (HIV)-seropositive men who have sex with men (MSM) are at higher risk of human papillomavirus (HPV) infection. This study was conducted to better understand the natural history of type-specific HPV infection in the anus. METHODS A cohort study was conducted among HIV-seropositive MSM in Montreal to investigate acquisition and loss of anal HPV infection. Participants were followed up every 6 months for 3 years for risk behaviors, HIV-related parameters, and HPV testing. RESULTS HPV DNA was detected in 97.9% of the 247 participants at baseline (median, 5 HPV types). The most common types were HPV-16 (38.2%) and HPV-6 (35.3%). Prevalent HPV-16 infections had the lowest clearance rate (12.2 cleared episodes per 1000 person-months [95% confidence interval {CI}, 8.5-17.7]) and a mean retention time of 36 months (95% CI, 32.7-38.8). The highest incidence rates were found for HPV-16 (10.8 new cases per 1000 person-months [95% CI, 8.0-14.7]), HPV-52 (10.8 new cases per 1000 person-months [95% CI, 8.2-14.1]), and HPV-53 (9.8 new cases per 1000 person-months [95% CI, 7.4-13.0]), with cumulative incidences at 36 months of approximately 30%. CONCLUSIONS Multiple HPV types were common in the anal canals of HIV-seropositive MSM. Incidence and clearance rates were not similar among HPV types. Ongoing surveillance of this cohort will help our understanding of the determinants of HPV persistence and progression to lesions.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011792 Quebec A province of eastern Canada. Its capital is Quebec. The region belonged to France from 1627 to 1763 when it was lost to the British. The name is from the Algonquian quilibek meaning the place where waters narrow, referring to the gradually narrowing channel of the St. Lawrence or to the narrows of the river at Cape Diamond. (From Webster's New Geographical Dictionary, 1988, p993 & Room, Brewer's Dictionary of Names, 1992, p440)
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001004 Anus Diseases Diseases involving the ANUS. Anus Disease,Disease, Anus,Diseases, Anus
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
March 2018, The Journal of infectious diseases,
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
August 2013, Sexually transmitted diseases,
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
January 2016, PloS one,
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
September 2013, Lancet (London, England),
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
January 2016, AIDS (London, England),
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
March 2011, Lancet (London, England),
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
January 2017, Infectious agents and cancer,
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
January 2014, Journal of the International AIDS Society,
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
November 2014, Journal of acquired immune deficiency syndromes (1999),
Alexandra de Pokomandy, and Danielle Rouleau, and George Ghattas, and Sylvie Vézina, and Pierre Coté, and John Macleod, and Guy Allaire, and Eduardo L Franco, and François Coutlée, and
August 2013, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!